CR11511A - Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado - Google Patents
Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardadoInfo
- Publication number
- CR11511A CR11511A CR11511A CR11511A CR11511A CR 11511 A CR11511 A CR 11511A CR 11511 A CR11511 A CR 11511A CR 11511 A CR11511 A CR 11511A CR 11511 A CR11511 A CR 11511A
- Authority
- CR
- Costa Rica
- Prior art keywords
- action profile
- delayed time
- insulin derivatives
- new insulin
- extremely delayed
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 230000003111 delayed effect Effects 0.000 title 1
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere a nuevos analogos de insulina con un perfil de tiempo/accion basal que se caracterizan por los rasgos de que a) el extremo de la cadena B consiste en un residuo aminoacido de caracter basico, amidado, tal como lisina o argininamida; b) el residuo de aminoacido N-terminal de la cadena A de la insulina en un residuo lisina o arginina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200810003568 DE102008003568A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| US4465908P | 2008-04-14 | 2008-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11511A true CR11511A (es) | 2010-09-13 |
Family
ID=40758369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11511A CR11511A (es) | 2008-01-09 | 2010-06-17 | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado |
Country Status (3)
| Country | Link |
|---|---|
| CR (1) | CR11511A (es) |
| DE (1) | DE102008003568A1 (es) |
| UA (1) | UA103015C2 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009038210A1 (de) | 2009-08-20 | 2011-03-03 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| DE102008051834A1 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9138462B2 (en) | 2009-07-31 | 2015-09-22 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
| NZ597964A (en) | 2009-07-31 | 2014-04-30 | Sanofi Aventis Deutschland | Long acting insulin composition |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| IN2014MN02304A (es) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| US20130323222A1 (en) | 2012-06-04 | 2013-12-05 | Matthew Charles | Human tissue kallikrein 1 glycosylation isoforms |
| IN2015DN00544A (es) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| CR20160376A (es) | 2014-01-20 | 2016-10-07 | Hanmi Pharm Ind Co Ltd | Insulina de acción prolongada y uso de la misma |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| JP7158378B2 (ja) | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少された、インスリンアナログ及びその用途 |
| AU2018230478B2 (en) | 2017-03-09 | 2025-01-23 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| KR102629006B1 (ko) | 2017-03-23 | 2024-01-25 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| GR1005153B (el) | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
| DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
| DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
| WO2004005342A1 (en) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
| AU2006291780B2 (en) | 2005-09-14 | 2011-12-08 | F. Hoffmann-La Roche Ag | Cleavage of precursors of insulins by a variant of trypsin |
-
2008
- 2008-01-09 DE DE200810003568 patent/DE102008003568A1/de not_active Withdrawn
-
2009
- 2009-01-06 UA UAA201009821A patent/UA103015C2/ru unknown
-
2010
- 2010-06-17 CR CR11511A patent/CR11511A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA103015C2 (ru) | 2013-09-10 |
| DE102008003568A1 (de) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR11511A (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| DOP2010000209A (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| CO6290770A2 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| PA8802301A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1 | |
| CY1121225T1 (el) | Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις | |
| CL2016000873A1 (es) | Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento. | |
| PE20150900A1 (es) | Derivados de exendida-4 como agonistas duales de glp1/glucagon | |
| CO6761400A2 (es) | Combinación de análogos de glucagón acilados con análogos de insulina | |
| GT201200230A (es) | Inhibidores del virus de la hepatitis c | |
| NI201200013A (es) | Composición de insulina de acción prolongada | |
| BRPI0923346A2 (pt) | Proteinas em super-helice antiparalela de cadeia simples | |
| CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| NI201300143A (es) | Coagonista del receptor de glucagón/glp-1 | |
| MX385001B (es) | Analogos de compstatina de celula reactiva, de accion prolongada u objetivos y usos de los mismos. | |
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| CR20130667A (es) | Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales | |
| MX2011011858A (es) | Composiciones borinicas. | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| AR082422A1 (es) | Composicion detergente liquida | |
| MX374468B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| CL2011002381A1 (es) | Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular | |
| CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. |